Findings From Landmark Resonate-2 Study Confirm Sustained Survival Benefit of Imbruvica® (Ibrutinib) for First-Line Chronic Lymphocytic Leukaemia Treatment With up to 10 Years Follow-up
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.